Inflammatory Disorders

        Anti-Complement – Catalyst Biosciences

Catalyst’s inflammation program is focused on a key activation component of inflammation, the complement cascade.  A cascade of multiple inflammatory mediators working in concert characterizes inflammation in ocular (AMD), cardiovascular and several other diseases, such as asthma and autoimmune disorders.  The Company has demonstrated the ability of its lead anti-complement Alterase™ Therapeutics to saturate several complement targets at far lower doses and with significantly greater effect than relevant benchmark antibodies in several animal models.

The anti-complement program is in preclinical animal model efficacy studies.